دورية أكاديمية
أعرض في EDS

Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight.

التفاصيل البيبلوغرافية
العنوان: Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight.
المؤلفون: Turkistani A; Department of Pharmacology and Toxicology, College of Medicine, Taif University, Taif, Saudi Arabia., Al-Kuraishy HM; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq., Al-Gareeb AI; Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.; Department of Clinical Pharmacology and Medicine, Jabir ibn Hayyan Medical University, Kufa, Iraq., Alexiou A; Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.; AFNP Med, Wien, Austria.; Department of Research & Development, Funogen, Athens, Greece.; University Centre for Research & Development, Chandigarh University, Punjab, India., Papadakis M; Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Wuppertal, Germany., Bahaa MM; Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt., Al-Windy S; Department of Biology, College of Science, Baghdad University, Baghdad, Iraq., Batiha GE; Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
المصدر: Immunity, inflammation and disease [Immun Inflamm Dis] 2024 Aug; Vol. 12 (8), pp. e1346.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: John Wiley and Sons Ltd Country of Publication: England NLM ID: 101635460 Publication Model: Print Cited Medium: Internet ISSN: 2050-4527 (Electronic) Linking ISSN: 20504527 NLM ISO Abbreviation: Immun Inflamm Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Oxford] : John Wiley and Sons Ltd, [2013]-
مواضيع طبية MeSH: Metformin*/therapeutic use , Metformin*/pharmacology , Atherosclerosis*/drug therapy , Atherosclerosis*/metabolism , Hypoglycemic Agents*/therapeutic use , Hypoglycemic Agents*/pharmacology , Kruppel-Like Transcription Factors*/metabolism , NF-E2-Related Factor 2*/metabolism , Diabetes Mellitus, Type 2*/drug therapy , Diabetes Mellitus, Type 2*/metabolism , Diabetes Mellitus, Type 2*/complications, Humans ; Animals ; Oxidative Stress/drug effects ; Signal Transduction/drug effects ; Reactive Oxygen Species/metabolism
مستخلص: Background: Atherosclerosis (AS) is a progressive disease that interferes with blood flow, leading to cardiovascular complications such as hypertension, ischemic heart disease, ischemic stroke, and vascular ischemia. The progression of AS is correlated with inflammation, oxidative stress, and endothelial dysfunction. Various signaling pathways, like nuclear erythroid-related factor 2 (Nrf2) and Kruppel-like factor 2 (KLF2), are involved in the pathogenesis of AS. Nrf2 and KLF2 have anti-inflammatory and antioxidant properties. Thus, activation of these pathways may reduce the development of AS. Metformin, an insulin-sensitizing drug used in the management of type 2 diabetes mellitus (T2DM), increases the expression of Nrf2 and KLF2. AS is a common long-term macrovascular complication of T2DM. Thus, metformin, through its pleiotropic anti-inflammatory effect, may attenuate the development and progression of AS.
Aims: Therefore, this review aims to investigate the possible role of metformin in AS concerning its effect on Nrf2 and KLF2 and inhibition of reactive oxygen species (ROS) formation. In addition to its antidiabetic effect, metformin can reduce cardiovascular morbidities and mortalities compared to other antidiabetic agents, even with similar blood glucose control by the Nrf2/KLF2 pathway activation.
Conclusion: In conclusion, metformin is an effective therapeutic strategy against the development and progression of AS, mainly through activation of the KLF2/Nrf2 axis.
(© 2024 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.)
References: Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):309-18. (PMID: 22827292)
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278. (PMID: 30938764)
Biomedicines. 2022 Aug 20;10(8):. (PMID: 36009579)
Biomedicines. 2021 Jul 28;9(8):. (PMID: 34440108)
J Am Heart Assoc. 2012 Dec;1(6):e002550. (PMID: 23316317)
Mol Aspects Med. 2020 Feb;71:100840. (PMID: 31882067)
Int J Mol Sci. 2021 May 28;22(11):. (PMID: 34071182)
Curr Atheroscler Rep. 2017 Aug 25;19(10):39. (PMID: 28842845)
Exp Ther Med. 2020 Sep;20(3):2245-2251. (PMID: 32765701)
Diabetes. 2015 Jun;64(6):2028-41. (PMID: 25552600)
Pharmacol Rev. 2021 Jul;73(3):924-967. (PMID: 34088867)
J Adv Pharm Technol Res. 2021 Jan-Mar;12(1):73-78. (PMID: 33532359)
PLoS One. 2014 Jul 02;9(7):e100778. (PMID: 24988476)
Int Immunopharmacol. 2022 Mar;104:108516. (PMID: 35032828)
Mol Cell Biochem. 2023 Aug 1;:. (PMID: 37526794)
J Exp Med. 2011 Feb 14;208(2):217-25. (PMID: 21242297)
J Pediatr Endocrinol Metab. 2015 May;28(5-6):649-55. (PMID: 25210757)
Eur J Immunol. 2011 Jul;41(7):2040-51. (PMID: 21484785)
Life Sci. 2018 Apr 1;198:56-64. (PMID: 29452166)
Lancet Diabetes Endocrinol. 2014 Feb;2(2):116-24. (PMID: 24622715)
Atherosclerosis. 2019 Feb;281:128-136. (PMID: 30658188)
Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1701-1712. (PMID: 31002870)
Biology (Basel). 2020 Mar 21;9(3):. (PMID: 32245238)
Acta Pharmacol Sin. 2018 Jul;39(7):1120-1132. (PMID: 29926844)
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6653-8. (PMID: 16617118)
Signal Transduct Target Ther. 2021 Jul 12;6(1):266. (PMID: 34253708)
Clin Pharmacokinet. 2011 Feb;50(2):81-98. (PMID: 21241070)
J Clin Med. 2020 Nov 21;9(11):. (PMID: 33233333)
Lipids. 2021 Jul;56(4):405-412. (PMID: 33881177)
Biomedicines. 2020 Dec 22;9(1):. (PMID: 33375185)
Eur J Pharmacol. 2020 Apr 5;872:172984. (PMID: 32017937)
Cell Mol Life Sci. 2020 May;77(10):1919-1932. (PMID: 31720740)
Eur J Med Res. 2013 Jun 24;18:19. (PMID: 23800095)
Front Pharmacol. 2012 Jul 19;3:119. (PMID: 22833723)
Peptides. 2014 Apr;54:19-26. (PMID: 24418070)
Exp Biol Med (Maywood). 2016 Feb;241(4):426-36. (PMID: 26490346)
Circ Res. 2022 Aug 19;131(5):424-441. (PMID: 35899624)
Diabetes. 2011 Nov;60(11):2683-4. (PMID: 22025774)
J Mol Cell Cardiol. 2022 Apr;165:54-63. (PMID: 34974060)
Trends Pharmacol Sci. 2020 Sep;41(9):598-610. (PMID: 32711925)
J Biol Chem. 2016 Oct 14;291(42):22288-22301. (PMID: 27417135)
Sci Rep. 2020 Sep 3;10(1):14555. (PMID: 32884086)
Metabolism. 2021 Jun;119:154766. (PMID: 33766485)
Cancer Sci. 2019 Apr;110(4):1256-1267. (PMID: 30689265)
Mediators Inflamm. 2020 Feb 17;2020:4634172. (PMID: 32148438)
Diagnostics (Basel). 2022 Aug 24;12(9):. (PMID: 36140453)
J Diabetes. 2020 Feb;12(2):102-104. (PMID: 31411812)
Immun Inflamm Dis. 2024 Aug;12(8):e1346. (PMID: 39092773)
Exp Ther Med. 2020 Aug;20(2):838-845. (PMID: 32742327)
J Am Heart Assoc. 2019 Mar 19;8(6):e011171. (PMID: 30866689)
AIDS. 2012 Mar 13;26(5):587-97. (PMID: 22112605)
Biochem Biophys Res Commun. 2021 Jun 11;557:334-341. (PMID: 33915432)
Int J Mol Sci. 2019 Jul 24;20(15):. (PMID: 31344980)
Diabetes Care. 2001 Mar;24(3):489-94. (PMID: 11289473)
J Am Heart Assoc. 2014 Dec;3(6):e001202. (PMID: 25527624)
Clin Pharmacokinet. 2020 Nov;59(11):1419-1431. (PMID: 32449077)
Diabetes Care. 2018 Dec;41(12):2570-2578. (PMID: 30275283)
Clin Lung Cancer. 2015 Jan;16(1):57-9. (PMID: 25242667)
PLoS One. 2018 Oct 26;13(10):e0205599. (PMID: 30365531)
Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. (PMID: 28615149)
Arch Intern Med. 2010 Nov 22;170(21):1892-9. (PMID: 21098347)
Nature. 2021 Apr;592(7855):524-533. (PMID: 33883728)
Cardiovasc Res. 2021 Apr 23;117(5):1295-1308. (PMID: 32667970)
Front Cardiovasc Med. 2021 May 20;8:644095. (PMID: 34124187)
Antioxidants (Basel). 2020 Apr 26;9(5):. (PMID: 32357465)
Diabetes Obes Metab. 2016 Oct;18(10):955-61. (PMID: 27265206)
Sci Rep. 2022 Jul 7;12(1):11570. (PMID: 35798762)
Free Radic Biol Med. 2015 Nov;88(Pt B):221-232. (PMID: 26117321)
Front Pharmacol. 2018 Sep 25;9:1082. (PMID: 30319417)
Int J Mol Sci. 2020 Feb 20;21(4):. (PMID: 32093292)
Nutr Metab (Lond). 2021 Jan 19;18(1):14. (PMID: 33468193)
Exp Ther Med. 2022 Oct 31;24(6):737. (PMID: 36478888)
Pediatrics. 2022 Nov 1;150(5):. (PMID: 36217888)
Biol Chem. 2019 May 27;400(6):711-732. (PMID: 30864421)
Cell Metab. 2018 Nov 6;28(5):679-688.e4. (PMID: 30244975)
Oxid Med Cell Longev. 2020 Sep 15;2020:5245308. (PMID: 33014272)
Biochem Pharmacol. 2020 Jul;177:114007. (PMID: 32360309)
Oxid Med Cell Longev. 2013;2013:104308. (PMID: 23691261)
Clin Pharmacol Ther. 2022 Sep;112(3):453-455. (PMID: 35687738)
Atherosclerosis. 2020 Aug;306:85-95. (PMID: 32654790)
Mol Nutr Food Res. 2020 Mar;64(6):e1901115. (PMID: 31965713)
Clin Pharmacol Ther. 2018 Nov;104(5):781-784. (PMID: 29761830)
Biomolecules. 2021 Dec 04;11(12):. (PMID: 34944478)
Lancet Diabetes Endocrinol. 2020 Jan;8(1):50-67. (PMID: 31582260)
Clin Pharmacol Ther. 2008 Nov;84(5):559-62. (PMID: 18401339)
Adv Chronic Kidney Dis. 2020 Jan;27(1):18-30. (PMID: 32146997)
Cell Death Dis. 2022 Sep 26;13(9):824. (PMID: 36163178)
Cerebrovasc Dis. 2019;48(3-6):226-235. (PMID: 31825937)
Nat Rev Cardiol. 2017 Feb;14(2):79-87. (PMID: 27905479)
JAMA. 2010 Apr 7;303(13):1303-4. (PMID: 20371790)
Eur J Pharmacol. 2022 Jun 5;924:174959. (PMID: 35430208)
Diabetes Care. 2021 Jun;44(6):1252-1253. (PMID: 34016611)
Oncotarget. 2016 Jan 26;7(4):4265-78. (PMID: 26673006)
Cardiovasc Diabetol. 2020 Mar 28;19(1):40. (PMID: 32222153)
J Diabetes. 2022 Dec;14(12):806-814. (PMID: 36444166)
Cell Stress Chaperones. 2023 Nov;28(6):657-673. (PMID: 37796433)
N Engl J Med. 2020 Aug 27;383(9):846-857. (PMID: 32846063)
Immun Inflamm Dis. 2023 Mar;11(3):e798. (PMID: 36988260)
معلومات مُعتمدة: Universität Witten/Herdecke
فهرسة مساهمة: Keywords: Kruppel like factor 2; atherosclerosis; metformin; nuclear erythroid related factor 2
المشرفين على المادة: 9100L32L2N (Metformin)
0 (Hypoglycemic Agents)
0 (Kruppel-Like Transcription Factors)
0 (NF-E2-Related Factor 2)
0 (KLF2 protein, human)
0 (Reactive Oxygen Species)
0 (NFE2L2 protein, human)
تواريخ الأحداث: Date Created: 20240802 Date Completed: 20240802 Latest Revision: 20240804
رمز التحديث: 20240804
مُعرف محوري في PubMed: PMC11295104
DOI: 10.1002/iid3.1346
PMID: 39092773
قاعدة البيانات: MEDLINE
الوصف
تدمد:2050-4527
DOI:10.1002/iid3.1346